Proton Intelligence Secures $6.95M to Revolutionize Cardio-Kidney Care
Slice of Healthcare Team
Jan 08, 2025
Key Highlights
- $6.95M Seed Financing led by SOSV, We Venture Capital, and others.
- CKM™ platform provides continuous potassium monitoring for cardio-kidney-metabolic diseases.
- Clinical studies underway for patients with CKD and ESRD.
- Transforming care by enabling timely data-driven decisions to prevent dyskalemia.
- Investors include SOSV, We Venture Capital, Tenmile, and others.
Source: Business Wire
Notable Quotes
“ The team's exceptional focus and relentless execution inspire confidence, and we are excited to continue to support them as they move into clinical validation. ”
Mohan S. Iyer, General Partner at SOSV
“ We Venture Capital have been impressed by this true breakthrough in electrolyte sensing capability, which will fulfil a critical gap in the current care continuum for many patients at risk from dyskalemia. ”
Dr. Louise Warme, Head at We Venture Capital
“ The ability to continuously monitor potassium will enable better data-driven decision-making for patients with late-stage chronic kidney disease or on dialysis, not only improving outcomes for these patients but saving health systems considerable costs. ”
Dr. Steve Burnell, Managing Director at Tenmile
